From a "Brain Function Map," a Look into Shulan Medical Group's Path of Technology

Title context: From a "Brain Function Map," a Look into Shulan Medical Group's Path of Technology Text: In June of this year, Mr. Wu, a Taiwanese businessman who has lived with Parkinson's disease for 13 years, came to Hangzhou and received individualized precision brain circuit stimulation therapy at Shulan (Hangzhou) Hospital, under Shulan Medical Group. After completing the full course of treatment, Mr. Wu's physical condition improved significantly, and he made a special trip to visit West Lake. When the gaze shifts from an individual to a broader population, a representative question emerges: in the face of highly complex brain diseases with enormous individual variation, how can the bottleneck of traditional standardized diagnosis and treatment be broken through? What kind of core carrier and systemic capability are needed for cutting-edge technologies to move toward large-scale clinical application? The "National Neuromodulation Precision Targeted Therapy Demonstration Center," jointly established by Shulan Medical Group and Galaxy Brain Science, provides a window for observation. Drawing a different "brain map" for each person The human brain is not a "standard part" manufactured according to a unified blueprint. For the same disease, the location, boundaries, and connectivity patterns of brain functional networks may differ across patients. If stimulation targets are identified solely based on group-averaged atlases, the degree of precision is inherently limited. The "National Neuromodulation Precision Targeted Therapy Demonstration Center," jointly established by Shulan Medical and Galaxy Brain Science, seeks to start from individual differences and, relying on functional magnetic resonance imaging (fMRI) and personalized Brain Functional Segmentation (pBFS) technology, overcome this precision medicine challenge through personalized treatment plans. From an industry perspective, this path shifts treatment from "finding targets by experience" to "finding targets by data," and from "treating the same disease the same way" to "treating the same disease differently." Scientific research keeps answering "why" and "how." What truly determines whether a technology can move from research results to medical services is whether it can enter the real-world diagnosis and treatment system and operate stably. This is also the value of Shulan Medical's cooperation with professional technology companies such as Galaxy Brain Science to drive technology from the laboratory to the clinic. The real threshold for implementation is not just a piece of equipment When a technology truly enters medical scenarios, the challenges it faces are far more complex than "buying a piece of equipment": technical effects in the laboratory still need further verification after entering real clinical scenarios. In 2025, Shulan Medical and Galaxy Brain Science jointly established the "National Neuromodulation Precision Targeted Therapy Demonstration Center." The full-cycle innovative diagnosis and treatment loop of "precision assessment-targeted modulation-long-term management" built through their collaboration aims to improve patients' diagnosis and treatment experience and provide a reusable framework for the large-scale application of the technology. In addition to process standardization, data governance is another threshold for technology implementation. The use of relevant imaging and clinical data must be carried out under the premise of compliance with laws and ethics, and links such as data de-identification and permission supervision are indispensable. For a technology-driven medical group like Shulan Medical, these seemingly non-technical links are precisely the indispensable foundational capabilities for technology implementation. From getting the process running smoothly in one campus to forming a relatively consistent diagnosis and treatment pathway across multiple campuses in different regions, a medical group is required to possess both high-quality core medical capabilities and standardized systemic capabilities in clinical process reengineering, multidisciplinary collaboration, and large-scale replication. A question worth asking is: why is the implementing party for this type of cooperation a private healthcare enterprise? Private healthcare enterprises are relatively flexible overall, and corporate operation provides an organizational carrier for the cross-regional replication of technology, allowing them to become hubs for clinical translation of technology. As part of the private healthcare sector, Shulan Medical's technology strategy balances independent research and development with open cooperation, introducing partners with an open mindset, providing clinical scenarios and multidisciplinary teams, and conducting data collaboration under compliant premises; partners such as Galaxy Brain Science provide technology and solutions, forming a complementary cooperation paradigm of "technology supply + scenario undertaking." This model can be seen as one of the samples of private healthcare forces participating in the construction of the national medical science and technology innovation system and implementing policies for the translation of scientific and technological achievements. The technology growth logic behind a "leaf" Taking a broader view, the National Neuromodulation Precision Targeted Therapy Demonstration Center is more like a leaf in Shulan Medical's technology layout. To understand this "leaf," it needs to be placed within the whole. In recent years, expressions such as computational medicine, artificial intelligence, translation of scientific research achievements, and full-life-cycle health management have appeared more and more frequently in Shulan Medical's strategic narrative. Its proposed "two-wheel drive" strategy points clearly: on the one hand, continue developing high-quality medical services; on the other hand, cultivate new growth space through technological innovation and industrial translation, responding to the national "innovation-driven development" strategy. In 2025, Shulan Medical announced the strategic upgrade of "All in Technology." The group's founder and president, Zheng Jie, proposed building a future medical model with computational medicine: taking data as the core production factor, integrating multiscale life mechanism modeling, statistical learning, and high-performance computing to establish a new medical logic of "self-developed systems-data-driven-AI empowerment," driving medicine from "treating illness" to "computing illness." The demonstration center happens to translate this grand logic into a practical sample. Clinical practice generates data, and with the assistance of cutting-edge technology, doctors formulate personalized precision treatment plans; scientific research projects inside and outside the hospital, under the premise of compliance with laws and ethics, drive the production of better research results, thereby forming a positive feedback loop of "clinical practice raises questions-technology seeks answers-the hospital completes translation." Shulan Medical undertakes technological innovation with clinical scenarios, providing scientific research achievements with the "last mile" channel from laboratory to clinic. From the perspective of industry trends, China's private healthcare sector is in a transition period from scale expansion to quality improvement. As China's healthcare reform continues to deepen, differentiated technological capabilities and service capabilities have become new dimensions of competition. Shulan Medical's choice to take computational medicine as its core is essentially to establish an advantage in the link of rapid translation of scientific and technological achievements through differentiated positioning: the hospital is not only a place for providing medical services, but also a testing ground and incubator for technological innovation; it undertakes technological innovation with clinical scenarios, is driven by computational medicine, and uses open cooperation as its mechanism to establish a virtuous cycle of innovation returns. From a business logic perspective, its core value lies in "reuse." Concepts represented by computational medicine help promote the application of validated technologies and processes, enabling clinical experience and technical solutions to be reused across regions and disciplines. This nonlinear growth potential is precisely the key to a technology-driven medical group. Today, as new quality productive forces become a key variable in the high-quality development of the healthcare industry, and as technological capabilities gradually become a core growth engine, China's emerging private healthcare forces represented by Shulan Medical are exploring another possibility.